Table 2 Two phase III studies investigating the role of adding oxaliplatin to preoperative chemoradiotherapy in rectal cancer
Study | Schema | N | Grade 3/4 toxicities (%) | LAR | pCR | Pathological metastatic disease (%) |
|---|---|---|---|---|---|---|
STAR-01 | Radiotherapy (59.4 Gy) and 5-fluorouracil | 379 | 8% | 72% | 16% | 3% |
(primary objective: | Â | Â | Â | Â | Â | Â |
overall survival) | Radiotherapy, 5-fluorouracil and oxaliplatin | 368 | 24% (p < 0.0001) | 73% | 16% | 0.5% |
ACCORD 12/0405 | Radiotherapy (45 Gy) and capecitabine | 299 | 11% | 73% | 14% | 4% |
PRODIGE 2 (primary | Â | Â | Â | Â | Â | Â |
objective: pCR) | Radiotherapy, capecitabine and oxaliplatin | 299 | 25% (p < 0.0001) | 76% | 19% | 3% |